Vigilant Biosciences recently CE Marked its OncAlert Oral Cancer RAPID Test, allowing the company to market the test in the European Union as well as Norway, Iceland, Liechtenstein and Switzerland.
The easy-to-use qualitative tool helps clinicians assess patients at risk for oral cancer, according to a press release. It is reportedly the first rapid test to detect a tumor-initiating and stem cell associated biomarker for head and neck cancer.
The test measures soluble CD44 and total protein levels. These specific protein markers indicate early stage cancers.
Patients expel the oral rinse into a cup, then a test cassette with a lateral flow test strip is inserted into the sample. The test only takes a few seconds to administer and in 20 minutes provides a colorimetric result that indicates the presence of CD44 and total protein with respect to pre-determined threshold levels for cutoffs in the specimen.
View Full Press Release
Source: Vigilant Biosciences